WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007001459) COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/001459    International Application No.:    PCT/US2005/041446
Publication Date: 04.01.2007 International Filing Date: 15.11.2005
IPC:
A61K 39/395 (2006.01)
Applicants: WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US) (For All Designated States Except US).
MURPHY, Kenneth, M. [US/US]; (US) (For US Only).
MURPHY, Theresa, L. [US/US]; (US) (For US Only).
SEDY, John, R. [US/US]; (US) (For US Only).
HURCHLA, Michelle, A. [US/US]; (US) (For US Only)
Inventors: MURPHY, Kenneth, M.; (US).
MURPHY, Theresa, L.; (US).
SEDY, John, R.; (US).
HURCHLA, Michelle, A.; (US)
Agent: LORENZ, Todd, A.; DORSEY & WHITNEY LLP, Suite 1000, 555 California Street, San Francisco, CA 94104-1513 (US)
Priority Data:
60/628,474 15.11.2004 US
Title (EN) COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
(FR) COMPOSITIONS ET PROCEDES POUR MODULER L'ACTIVITE LYMPHOCYTAIRE
Abstract: front page image
(EN)The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided.
(FR)La présente invention concerne découle de l'identification du médiateur HVEM comme étant le ligand natif de l'atténuateur lymphocytaire BTLA. L'invention propose ainsi des compositions et procédés permettant une modulation des interactions entre BTLA et HVEM ainsi qu'une modulation de l'activité des BTLA et HVEM, qui son utiles à la modulation des réponses immunitaires. L'invention concerne également des agonistes et antagonistes de l'interaction entre BTLA et HVEM, ainsi que des procédés permettant de traiter divers états par une modulation des réponses immunitaires.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)